November 30, 2016 - By Adrian Mccoy
In a analysts report revealed to clients and investors on Wednesday, 30 November, professional analysts at PiperJaffray’s research division lowered Arrowhead Research Corporation (NASDAQ:ARWR)‘s stock rating from a”Overweight” to “Neutral”.
Out of 3 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $20.0 is the highest target while $8 is the lowest. The $14.33 average target is 874.83% above today’s ($1.47) stock price. Arrowhead Research Corp has been the topic of 5 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) on Thursday, November 10 with “Buy” rating. Cantor Fitzgerald initiated Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) on Friday, August 19 with “Buy” rating. The rating was maintained by Piper Jaffray with “Overweight” on Friday, September 25. Chardan Capital Markets initiated the stock with “Buy” rating in Thursday, May 19 report. RBC Capital Markets maintained Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) on Wednesday, August 5 with “Hold” rating.
About 14.66M shares traded hands or 1131.93% up from the average. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has declined 26.09% since April 27, 2016 and is downtrending. It has underperformed by 31.32% the S&P500.
Analysts await Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report earnings on December, 12. They expect $-0.33 earnings per share, up 21.43% or $0.09 from last year’s $-0.42 per share. After $-0.32 actual earnings per share reported by Arrowhead Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 3.13% negative EPS growth.
Insitutional Activity: The institutional sentiment is 0 in Q2 2016. Its the same as in 2016Q1. The ratio is the same, as 67 funds sold all Arrowhead Pharmaceuticals Inc shares owned while 0 reduced positions. only 0 funds bought stakes while 0 increased positions. They now own 6,170 shares or 99.97% less from 18.16 million shares in 2016Q1.
Hanson And Doremus Invest Mngmt has 470 shares for 0% of their US portfolio. Moreover, Great West Life Assurance Co Can has 0% invested in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) for 5,700 shares.
Insider Transactions: Since August 22, 2016, the stock had 0 insider purchases, and 1 sale for $160,000 net activity. Shares for $160,000 were sold by Myszkowski Kenneth Allen on Monday, August 22.
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The company has a market cap of $87.90 million. The Firm is engaged in developing RiboNucleic Acid interference therapeutics. It currently has negative earnings. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA.
According to Zacks Investment Research, “Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.”
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, incorporated on February 13, 2001, is a biopharmaceutical company. The Firm is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi therapeutics leverage this natural pathway of gene silencing to target and shut down specific disease causing genes. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. The Company’s ARC-520 is an RNAi therapeutic designed to treat chronic hepatitis B virus (HBV) infection by reducing the expression and release of new viral particles and viral proteins with the goal of achieving a functional cure for HBV. The Firm is conducting multiple Phase IIb clinical efficacy studies. The Company’s ARC-AAT is an unlocked nucleobase analog (UNA), which contains RNAi therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that can damage the liver and lungs of affected individuals. The Firm is conducting a Phase Ib clinical trial for ARC-AAT. The study is a multi-center, randomized, placebo-controlled, double blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels.
More notable recent Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) news were published by: Nasdaq.com which released: “Here’s Why Arrowhead Pharmaceuticals Inc. Is Being Obliterated Today” on November 30, 2016, also Fool.com with their article: “Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today” published on November 09, 2016, Fool.com published: “What’s Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown?” on November 10, 2016. More interesting news about Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) were released by: Businesswire.com and their article: “Arrowhead Pharmaceuticals Announces Closing of License and Collaboration …” published on November 21, 2016 as well as Prnewswire.com‘s news article titled: “ARWR LOSS ALERT: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc …” with publication date: November 22, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy